Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.

ABSTRACT: No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.

SUBMITTER: Domling A 

PROVIDER: S-EPMC4104593 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature